-

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Monday, January 13, 2025.

The company’s presentation and participation in a fireside chat will begin at 7:30 a.m. PT/10:30 a.m. ET.

The event will be webcast simultaneously at http://investor.bms.com, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the conclusion of the event.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Summary
Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
Release Versions
English

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years...

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM...

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

PRINCETON, N.J.--(BUSINESS WIRE)--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy....
Back to Newsroom